<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01110616</url>
  </required_header>
  <id_info>
    <org_study_id>3134-010</org_study_id>
    <secondary_id>MK3134-010</secondary_id>
    <nct_id>NCT01110616</nct_id>
  </id_info>
  <brief_title>EEG (Electroencephalogram) Platform Standardization in Healthy Male Subjects (3134-010)</brief_title>
  <official_title>A Double Blind, Randomized, Crossover Study to Assess EEG Platform Standardization in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to test the experimental reproducibility and within-subject
      variability of qEEG (quantitative electroencephalogram) using two probe compounds: MK3134 and
      lorazepam.

      This study will test the hypothesis that EEG (Electroencephalogram) theta power, averaged
      across a topographical region of interest is decreased 6 hours after administration of MK3134
      compared to placebo.

      The objective of this study is to test the experimental reproducibility and within-subject
      variability of qEEG using two probe compounds: MK3134 and lorazepam.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EEG (Electroencephalogram) theta power averaged across a topographical region of interest 6 hours after administration of MK3134/placebo</measure>
    <time_frame>Baseline and 6 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>EEG (Electroencephalogram) beta and sigma power averaged across all cortical leads 2 hours after administration of lorazepam/placebo</measure>
    <time_frame>Baseline and 2 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK3134-Lorazepam-Placebo-MK3134-Lorazepam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK3134-Lorazepam-Placebo-Lorazepam-MK3134</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK3134-Placebo-Lorazepam-MK3134-Lorazepam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK3134-Placebo-Lorazepam-Lorazepam-MK3134</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lorazepam-Placebo-MK3134-MK3134-Lorazepam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lorazepam-Placebo-MK3134-Lorazepam-MK3134</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lorazepam-MK3134-Placebo-MK3134-Lorazepam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lorazepam-MK3134-Placebo-Lorazepam-MK3134</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo-MK3134-Lorazepam-MK3134-Lorazepam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo-MK3134-Lorazepam-Lorazepam-MK3134</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo-Lorazepam-MK3134-MK3134-Lorazepam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo-Lorazepam-MK3134-Lorazepam-MK3134</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK3134</intervention_name>
    <description>MK3134, 25 mg tablets (5 x 5 mg capsule), orally</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
    <arm_group_label>Sequence 7</arm_group_label>
    <arm_group_label>Sequence 8</arm_group_label>
    <arm_group_label>Sequence 9</arm_group_label>
    <arm_group_label>Sequence 10</arm_group_label>
    <arm_group_label>Sequence 11</arm_group_label>
    <arm_group_label>Sequence 12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Lorazepam</intervention_name>
    <description>Lorazepam, 2 mg (2 x 1 mg tablet), orally</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
    <arm_group_label>Sequence 7</arm_group_label>
    <arm_group_label>Sequence 8</arm_group_label>
    <arm_group_label>Sequence 9</arm_group_label>
    <arm_group_label>Sequence 10</arm_group_label>
    <arm_group_label>Sequence 11</arm_group_label>
    <arm_group_label>Sequence 12</arm_group_label>
    <other_name>Lorazepam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <description>Placebo, to match MK3134, and placebo to match Lorazepam</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
    <arm_group_label>Sequence 7</arm_group_label>
    <arm_group_label>Sequence 8</arm_group_label>
    <arm_group_label>Sequence 9</arm_group_label>
    <arm_group_label>Sequence 10</arm_group_label>
    <arm_group_label>Sequence 11</arm_group_label>
    <arm_group_label>Sequence 12</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is a male between 18 to 40 years of age

          -  The subject has a Body Mass Index (BMI) greater than or equal to 31 kg/m^2 at the
             prestudy (screening) visit

          -  Subject has normal or corrected to normal visual and auditory acuity

          -  Subject has been a nonsmoker and/or has not used nicotine or nicotine-containing
             products for at least approximately 6 months

          -  Subject is right-handed

        Exclusion Criteria:

          -  Subject has permanent cosmetic or metallic objects in their body that can interfere
             with the measurements

          -  Subject has a history of stroke, chronic seizures, or major neurological disorder

          -  Subject has a history of neoplastic disease

          -  Subject has a current diagnosis of or a prior history of sleep apnea

          -  Subject has a history of fainting during blood draws

          -  Subject has a history of significant head injury/trauma

          -  Subject has a current diagnosis of or history of Bipolar illness, Schizophrenia,
             Attention Deficit Hyperactivity Disorder (ADHD), or claustrophobia

          -  Subject works a night shift and is not able to avoid night shift work within 3 days
             before each treatment visit

          -  Subject is currently a regular user of any illicit drugs or has a significant history
             of drug (including alcohol) abuse
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Belgium</country>
  </removed_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2010</study_first_submitted>
  <study_first_submitted_qc>April 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2010</study_first_posted>
  <last_update_submitted>October 30, 2015</last_update_submitted>
  <last_update_submitted_qc>October 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EEG Standardization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lorazepam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

